A joint analysis team of the Korea Advanced Institute of Science and Technology and home biotechnology agency Neogenlogic has developed a brand new synthetic intelligence model that may assist produce an entire new kind of “personalized” cancer vaccine, the joint team mentioned Friday.
The new AI platform helps determine neoantigens distinctive to every cancer affected person that may practice the affected person’s immune system, and thus forestall recurrence of the sickness.
“Neoantigens — mutation-derived protein fragments unique to a patient’s tumor — are the ‘fingerprints’ used by vaccines to train the immune system,” the team, led by professor Choi Jung-kyoon of KAIST, mentioned in a press launch.
“While current vaccines focus almost exclusively on activating cytotoxic T cells for immediate attack, emerging clinical evidence highlights that B cell-mediated immune memory is the key to durable, long-term antitumor responses and the prevention of recurrence,” it added.
Such findings had been revealed within the Dec. 3 version of Science Advances, a peer-reviewed scientific journal.
According to the analysis team, its AI model predicts which neoantigens will set off a “robust B cell response” by studying the structural interplay patterns between mutant peptides and B cell receptors.
“The study introduces the world’s first AI framework capable of predicting B cell immunogenicity alongside T cell responses for the design of personalized cancer vaccines,” it mentioned.
Professor Choi highlighted the importance of the examine in that it supplied empirical proof on the significance of B cells in creating cancer vaccines.
“While the academic community was aware that studying B cells is important in developing cancer vaccines, there were no tools to verify the concept,” Choi informed Yonhap News Agency.
Neogenlogic mentioned in a separate launch that the brand new expertise has been validated towards “large-scale genomic datasets and clinical trial data from global vaccine leaders,” including the brand new AI framework has additionally been totally built-in into its proprietary discovery engine DeepNeo.
Choi mentioned his team is making ready an investigational new drug submission with the U.S. Food and Drug Administration, with plans to enter scientific trials in 2027.
“Together with Neogenlogic, we are translating this academic breakthrough into a clinical-grade platform,” he added. “Our proprietary AI elevates the scientific rigor of neoantigen selection, moving us from theoretical prediction to systematic clinical application.” (Yonhap)